Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Joshua Maher, PhD
Element Materials Technology/Jones Microbiology Institute
Poster(s):
(P-1360) Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1361) Cefiderocol Activity against
Pseudomonas aeruginosa
, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1362) Cefiderocol Activity against Carbapenem-resistant
Acinetobacter baumannii-calcoaceticus
complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1363) Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1484)
In vitro
Activity of Cefiderocol and Comparator Agents Against Non-fermentative Gram-negative Bacilli Isolated from Patients Hospitalized with Pneumonia as part of the SENTRY Global Surveillance Program (2020-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1526)
In vitro
Activity of Ceftobiprole Against Prominent Methicillin-resistant
Staphylococcus aureus
Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1527) Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020).
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT